ObsEva Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 53
Employees
  • Stock Symbol
  • OBSV
Stock Symbol
  • Share Price
  • $2.62
  • (As of Thursday Closing)

ObsEva General Information

Description

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The company is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. The is developing OBE2109 as a novel, oral gonadotropin-releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Chemin des Aulx, 12
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022 000 00 00

ObsEva Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ObsEva Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.62 $2.62 $1.63 - $10.35 $123M 48M 1.15M -$2.39

ObsEva Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 242,136 103,390 392,274 294,043
Revenue 0 0 0 0
EBITDA (84,807) (106,358) (77,045) (67,394)
Net Income (88,386) (108,790) (76,716) (66,926)
Total Assets 79,198 103,943 167,440 135,235
Total Debt 26,983 27,076 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ObsEva Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ObsEva‘s full profile, request access.

Request a free trial

ObsEva Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therap
Biotechnology
Geneva, Switzerland
53 As of 2019
00000
00000000 00000

000000

co laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupt
0000 000000000
San Diego, CA
00 As of 0000
00000
000000 - 000 00000

000000 0

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000 000000000
The Woodlands, TX
0 As of 0000
000.00
00.00 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ObsEva Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evofem Formerly VC-backed San Diego, CA 00 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed The Woodlands, TX 0 000.00 000000&0 000.00
00000000 Venture Capital-Backed New York, NY 00 000.00 0000000000 0 000.00
0000000 0000000000 Corporation San Diego, CA 00 00000 000000 - 000 00000
To view ObsEva’s complete competitors history, request access »

ObsEva Executive Team (15)

Name Title Board Seat Contact Info
Ernest Loumaye Ph.D Chief Executive Officer & Founder
Timothy Adams Chief Financial Officer, Finance
Fabien de Ladonchamps Interim Chief Financial Officer
Jean-Pierre Gotteland Ph.D Chief Scientific Officer & Executive
Wim Souverijns Ph.D Chief Commercial Officer
You’re viewing 5 of 15 executive team members. Get the full list »

ObsEva Board Members (11)

Name Representing Role Since
Annette Clancy Self Board Member 000 0000
Edward Mathers Self Board Member 000 0000
Frank Verwiel MD Self Chairman & Board Member 000 0000
Jacky Vonderscher Ph.D Self Board Member 000 0000
James Healy MD Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ObsEva Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ObsEva Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ObsEva‘s full profile, request access.

Request a free trial